Investors

Investors

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Latest Press Releases

Date Title and Summary
Toggle Summary Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent
Multi-center Decision Impact Study of Genomic Health's Prostate Cancer Test Underscores Opportunity for More Precise Management of Low-risk Disease
Toggle Summary Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit
The 13th St. Gallen International Expert Consensus Panel Report Emphasizes Oncotype DX's Unsurpassed Clinical Validation Supporting Greater Use and Reimbursement of the Test Worldwide
Toggle Summary Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
Oncotype DX® Test Endorsed for Guiding Treatment Decisions on Adjuvant Chemotherapy Both in Node-negative and in Node-positive Disease Gene Expression Signatures Recommended for the First Time as Preferable to Standard Pathology When Adequate Reproducibility is Not Granted
Toggle Summary UCSF-led Study Shows Oncotype DX® and MRI May Provide Independent Information in Favorable Risk Prostate Cancer
Presentation at American Urological Association 2015 Annual Meeting Reconfirms Oncotype DX Genomic Prostate Score as Independent Predictor of Adverse Pathology

DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.